Key Events This Week
Mar 02: Stock opens at Rs.1,221.55, declines 1.83% amid broad market sell-off
Mar 04: Technical indicators signal bearish momentum; stock gains 0.50%
Mar 05: Downgrade to Strong Sell by MarketsMOJO announced; stock slips 0.23%
Mar 06: Week closes at Rs.1,206.30, up 0.32% on the day but down for the week
Monday, 2 March 2026: Market Sell-Off Hits Concord Biotech
Concord Biotech opened the week at Rs.1,221.55 but faced immediate pressure, closing at Rs.1,199.15, down 1.83%. This decline was in line with the broader market, as the Sensex fell 1.41% to 35,812.02 amid widespread selling. The stock’s volume was moderate at 50,613 shares, reflecting cautious investor sentiment. The initial drop set a bearish tone for the week, with the stock retreating from recent highs and signalling vulnerability.
Wednesday, 4 March 2026: Bearish Technical Momentum Emerges
After no trading data on Tuesday, Concord Biotech rebounded slightly on Wednesday, gaining 0.50% to close at Rs.1,205.20. However, this modest gain masked a deteriorating technical picture. Key indicators such as moving averages turned bearish, and momentum oscillators signalled increasing downside pressure. The stock traded in a volatile range between Rs.1,166.40 and Rs.1,224.95 during the day, reflecting uncertainty. Meanwhile, the Sensex declined sharply by 1.92% to 35,125.64, indicating broader market weakness.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Thursday, 5 March 2026: Downgrade to Strong Sell Amid Weak Financials
The stock slipped 0.23% to Rs.1,202.40 on Thursday despite a strong market rebound, with the Sensex rising 1.29% to 35,579.03. This underperformance coincided with the announcement of a downgrade by MarketsMOJO from Sell to Strong Sell, reflecting deteriorating financial results and bearish technical signals. Concord Biotech reported a 15.9% decline in Profit Before Tax and a 17.4% drop in Net Profit After Tax in recent quarters, alongside negative operating profit growth over five years. The downgrade was driven by these weak fundamentals combined with technical indicators such as bearish MACD and moving averages, signalling heightened risk.
Friday, 6 March 2026: Week Ends with Slight Recovery but Negative Trend Persists
Concord Biotech closed the week at Rs.1,206.30, up 0.32% on Friday, while the Sensex declined 0.98% to 35,232.05. The stock’s volume was low at 6,169 shares, indicating limited buying interest. Despite the intraday gain, the weekly performance remained negative at -1.25%, contrasting with the Sensex’s larger 3.00% decline. Technical indicators continued to reflect bearish momentum, with the stock trading well below its 52-week high of Rs.2,149.90. The downgrade to Strong Sell and weak financial trends suggest ongoing challenges ahead.
Why settle for Concord Biotech Ltd? SwitchER evaluates this small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Weekly Price Performance: Concord Biotech vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-02 | Rs.1,199.15 | -1.83% | 35,812.02 | -1.41% |
| 2026-03-04 | Rs.1,205.20 | +0.50% | 35,125.64 | -1.92% |
| 2026-03-05 | Rs.1,202.40 | -0.23% | 35,579.03 | +1.29% |
| 2026-03-06 | Rs.1,206.30 | +0.32% | 35,232.05 | -0.98% |
Key Takeaways
Bearish Technical Momentum: The stock’s technical indicators, including MACD, moving averages, and Bollinger Bands, have shifted decisively bearish. This suggests continued downside risk despite occasional intraday recoveries.
Downgrade to Strong Sell: The MarketsMOJO downgrade reflects deteriorating financial performance, with consecutive quarterly profit declines and negative operating profit growth over five years. The Mojo Score fell to 28.0, signalling heightened caution.
Valuation Concerns: Despite weak earnings, Concord Biotech trades at a high Price to Book ratio of 7, indicating expensive valuation relative to fundamentals and sector peers.
Relative Outperformance vs Sensex: While the stock declined 1.25% for the week, it outperformed the Sensex’s 3.00% fall, suggesting some resilience amid broader market weakness.
Volume and Market Interest: Trading volumes were uneven, with low activity on days of price gains, indicating limited conviction behind rallies.
Conclusion
Concord Biotech Ltd’s week was marked by a continuation of bearish technical signals and a significant downgrade to Strong Sell, driven by weak financial results and deteriorating market sentiment. Although the stock marginally outperformed the Sensex’s steep decline, the underlying fundamentals and technical indicators point to ongoing challenges. Elevated valuation metrics further complicate the outlook, suggesting limited upside potential in the near term. Investors should remain cautious and monitor developments closely as the stock navigates a difficult phase amid sector headwinds and broader market volatility.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
